09:52 AM EST - Theralase Technologies Inc. : Has submitted an Investigational Testing Authorization (“ITA”) for its anti-cancer technology to Health Canada for approval. The ITA details information about the proprietary Theralase TLC-3200 Oncology Laser System, which Theralase plans to use to activate the Company’s lead Photo Dynamic Compound, TLD-1433, to destroy Non-Muscle Invasive Bladder Cancer. Theralase Technologies Inc.
shares V.TLT are trading down $0.005 at $0.36.
